Navigation Links
Biotel Announces Record Revenues and Earnings for Fiscal 2008
Date:9/30/2008

MINNEAPOLIS, Sept. 30 /PRNewswire-FirstCall/ -- Biotel Inc. (OTC Bulletin Board: BTEL) announced results for the year ended June 30, 2008, with net earnings of $666,000, or $0.23 per diluted share, on revenues of $11,495,000. This compares to net earnings of $520,000, or $0.19 per share, on revenues of $11,233,000 for the prior year. For its fourth quarter, the company reported net earnings of $191,000, or $0.07 per diluted share, on revenues of $3,187,000. This compares to net earnings of $221,000, or $0.08 per diluted share, on revenues of $3,115,000 in the fourth quarter of 2007.
Highlights for the quarter and year are as follows:

-- Sixth year in a row of profitable growth.

-- Record sales for the fourth quarter and year

-- Net income for the year up 28.1 percent over 2007

-- Gross margin for the year was 44.4% versus 42.6% last year

"Biotel achieved a record fiscal year in revenues and earnings with a strong improvement in the fourth quarter over the third quarter," Biotel President and CEO Steve Springrose said. "Our Braemar Holter devices, event recorders, liposuction and other medical devices made strong revenue contributions, and our Agility 24/7 cardiac monitoring services continued to make very strong year over year gains. The highlight of the quarter was the introduction of our new ER920W cardiac arrhythmia monitor, our first entry into the high potential wireless market. Very importantly, we have already received FDA 510(k) approval of our next generation wireless monitor employing 'Fusion' technology, scheduled for product introduction early in calendar 2009. Biotel serves as a development partner to medical corporations seeking new devices and clinical research services."

3 months ended 3 months ended %

June 30, 2008 June 30, 2007 Change

Revenues $3,187,000 $3,115,000 2.3%

Net Income $191,000 $221,000 (13.6%)

Earnings Per Share, Basic $.07 $0.08

Earnings Per Share, Diluted $.07 $0.08

12 months ended 12 months ended %

June 30, 2008 June 30, 2007 Change

Revenues $11,495,000 $11,233,000 2.3%

Net Income $666,000 $520,000 28.1%

Earnings Per Share, Basic $.25 $0.20

Earnings Per Share, Diluted $.23 $0.19


'/>"/>
SOURCE Biotel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... and CAMBRIDGE, Mass. ... , Dec. 4, 2016 SystemOne, a ... diagnostics software platforms for the developing world, and ... Care.™" a reality with its portable and ultrasensitive ... into a development and license agreement to integrate ...
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... today announced the submission of a Marketing Authorization Application (MAA) ... biosimilar candidate to Avastin ® (bevacizumab). The companies believe ... the EMA. "The submission of ABP 215 ... to expand our oncology portfolio," said Sean E. Harper ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) ... Antonio Breast Cancer Symposium. Using molecular test results from tumors with previously ...
(Date:12/2/2016)... OF PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... research is through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets ... convened more than 100 clinical trial leaders from over 40 sponsor, CRO and site ...
Breaking Biology Technology:
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
(Date:11/15/2016)... Nov. 15, 2016  Synthetic Biologics, Inc. (NYSE ... focused on the gut microbiome, today announced the ... shares of its common stock and warrants to ... a price to the public of $1.00 per ... Biologics from the offering, excluding the proceeds, if ...
(Date:11/14/2016)... , Nov. 14, 2016  Based ... identification market, Frost & Sullivan recognizes FST ... Sullivan Award for Visionary Innovation Leadership. FST ... the biometric identification market by pioneering In ... solution for instant, seamless, and non-invasive verification. ...
Breaking Biology News(10 mins):